Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of AVTX-002 for the Treatment of Poorly Controlled Non-Eosinophilic Asthma

NCT05288504 is registered in ClinicalTrials.gov with Avalo Therapeutics, Inc. as lead sponsor.

NCT NCT05288504
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05288504 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of AVTX-002 for the Treatment of Poorly Controlled Non-Eosinophilic Asthma
Lead sponsor
Avalo Therapeutics, Inc.
Phase
Phase 2
Overall status
Completed
Start date
February 24, 2022
Completion date
May 11, 2023
Enrollment
91 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

non-eosinophilic asthma